3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Cyclophosphamide
4
pembrolizumab
3
Nivolumab
3
regorafenib
2
fludarabine
2
SS1(dsFv)PE38
2
Ipilimumab
2
Hyperthermic Intraperitoneal Chemotherapy
2
Doxorubicin
2
Decitabine
2
Cisplatin
2
tislelizumab
1
sodium thiosulfate
1
sargramostim
1
entinostat
1
durvalumab
1
cemiplimab
1
bemcentinib
1
avelumab
1
atezolizumab
1
alvocidib
1
alanosine
1
X-Rays
1
Tetrahydrouridine
1
Tamoxifen
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Specimen Handling
1
Referral and Consultation
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Blood Component Removal
×
Gastrointestinal
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled